tldrdailynews.com logo
Tag

Weightloss

All articles tagged with #weightloss

Ozempic Users See Drop in Daily Steps After GLP-1 Start
health1 month ago

Ozempic Users See Drop in Daily Steps After GLP-1 Start

Using All of Us data, researchers analyzed 753 obesity patients prescribed GLP-1 medications (including semaglutide/Ozempic and tirzepatide) who had Fitbit data before/after starting therapy. After initiation, average daily steps fell from 5,047 to 4,487 and moderate-to-vigorous activity dropped from 28 minutes to 22 minutes, suggesting exercise promotion should accompany pharmacologic treatment. The findings are preliminary (to be presented at ENDO 2026) and older adults or those with musculoskeletal pain may be at higher risk for muscle loss.

via Gizmodo|
#exercise#fitbit#glp-1s
Retatrutide: promising weight loss but with safety and access caveats
health3 months ago

Retatrutide: promising weight loss but with safety and access caveats

Retatrutide is an experimental peptide that may drive substantial weight loss by modulating appetite and metabolism, but it is not approved anywhere, carries gastrointestinal and mood-related risks, and unregulated online access raises safety concerns; achieving a shredded appearance still depends on resistance training and a protein-rich diet under medical supervision.

via The Conversation|
#health#obesity#regulation
BRP: A natural brain-targeted appetite suppressor with Ozempic-like promises
science3 months ago

BRP: A natural brain-targeted appetite suppressor with Ozempic-like promises

Stanford researchers report that BRP, a 12‑amino‑acid peptide discovered via AI, suppresses appetite by acting on the hypothalamus, leading to reduced food intake and fat loss in animals with no major side effects, potentially offering a more targeted obesity treatment than Ozempic; human trials are planned after animal safety and efficacy are demonstrated.

via ScienceDaily|
#brain#brp#obesity
Real-World Data Show Minimal Weight Regain After Stopping GLP-1 Obesity Drugs
health4 months ago

Real-World Data Show Minimal Weight Regain After Stopping GLP-1 Obesity Drugs

A Cleveland Clinic study of nearly 8,000 adults who stopped GLP-1 medications (such as Ozempic or tirzepatide) found only modest weight regain after one year (average 0.5%), suggesting real-world outcomes may diverge from clinical trials. Many patients either stay on some form of obesity treatment or switch to alternatives, with weight loss largely maintained when ongoing care and lifestyle support are in place, though results vary across populations and settings.

via Fox News|
#glp-1#health#ozempic
GLP-1 Weight-Loss Drugs May Trigger Scurvy if Diet Slips, Experts Warn
health4 months ago

GLP-1 Weight-Loss Drugs May Trigger Scurvy if Diet Slips, Experts Warn

Reports of scurvy linked to GLP-1 weight‑loss drugs have risen as these medications curb appetite and food intake, potentially causing vitamin C and other nutrient deficiencies. Experts note that malnutrition risk increases when appetite suppression leads to reduced consumption, and advise nutritional status assessment, meal planning with a dietitian, and targeted supplementation (e.g., vitamin C 100–200 mg) to prevent scurvy and other deficiencies while continuing GLP-1 therapy. Scurvy is reversible with proper supplementation and dietary adjustments.

via Healthline|
#glp-1#health#malnutrition
Novo Nordisk stock slides after CagriSema misses non-inferiority vs Lilly’s tirzepatide
business4 months ago

Novo Nordisk stock slides after CagriSema misses non-inferiority vs Lilly’s tirzepatide

Novo Nordisk’s stock fell about 15% after its weight‑loss candidate CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide over 84 weeks (23% weight loss on CagriSema vs 25.5% for tirzepatide at 84 weeks). Lilly’s drug remains dominant in the market, and Novo is pursuing higher‑dose trials while facing competition, U.S. price pressure, and looming loss of exclusivity for Wegovy and Ozempic. The stock traded at its lowest since June 2021, and Lilly stock rose in premarket trading as Novo cautioned about slower growth in 2026.

via CNBC|
#business#cagrisema#novonordisk
Front-loading calories at breakfast linked to weight loss in small study
health5 months ago

Front-loading calories at breakfast linked to weight loss in small study

A small randomized crossover trial in adults with overweight/obesity found that eating 45% of daily calories at a large breakfast and 20% at dinner led to weight loss over 28 days, with two plan variants—high-protein (less hungry) and high-fiber (slightly more weight loss and greater gut microbiome diversity). The high-fiber group lost about 4.87 kg and the high-protein group about 3.87 kg; both improved blood pressure and lipids. Limitations include a small, mostly male sample and short duration, so longer, larger studies are needed, with personalization and consideration of circadian factors.

via Medical News Today|
#breakfast#fiber#health
Risks of Discontinuing GLP-1s Revealed
health6 months ago

Risks of Discontinuing GLP-1s Revealed

Many users of GLP-1 drugs like Ozempic struggle to stop using them due to intense hunger and weight regain, suggesting a potential lifelong dependency. While some, like Ellen Ogley, maintain weight loss through lifestyle changes, others experience significant weight regain, highlighting the importance of healthy habits during treatment. Experts recommend developing an exit strategy that includes lifestyle modifications to sustain weight loss after discontinuing the medication.

via Yahoo News New Zealand|
#dependency#glp-1#health